PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum

被引：16
|
作者：
Goel, S. [1 ]
Krop, I. E. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 08期
关键词：
D O I：
10.1093/annonc/mdw246
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1368 / 1372
页数：5
相关论文
共 50 条
  • [1] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [3] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    [J]. British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [4] Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
    Zouein, Joseph
    Noujaim, Charbel
    Kourie, Hampig Raphael
    [J]. BIOMARKERS IN MEDICINE, 2021, 15 (09) : 609 - 613
  • [5] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
    Guarneri, V.
    Dieci, M. V.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Nanni, O.
    Piacentini, F.
    Orvieto, E.
    Curtarello, M.
    Chic, N.
    D'Amico, R.
    Prat, A.
    Conte, P. F.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S23 - S23
  • [6] Prognostic value of PIK3CA mutations in HER2-positive early stage breast cancer: A French cohort study.
    Coussy, Florence
    Lehmann-Che, Jacqueline
    Sanna, Alice
    Giacchetti, Sylvie
    Bertheau, Philippe
    Cuvier, Caroline
    Lalloum, Marjorie
    Poirot, Brigitte
    de Roquancourt, Anne
    Bouhidel, Fatiha
    Rigon, Matthieu Resche
    Espie, Marc
    Teixeira, Luis
    de Cremoux, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis
    Seo, Y. -J.
    Yu, J. -H.
    Kim, S. -W.
    Lee, J. -E.
    Nam, S. -J.
    Cho, S. -Y.
    Cho, E. -Y.
    [J]. VIRCHOWS ARCHIV, 2017, 471 : S61 - S61
  • [8] Decreased PTEN expression and PIK3CA mutations in HER-2 positive breast cancer.
    Koninki, K.
    Kauraniemi, P.
    Pitkanen, J.
    Isola, J.
    Tanner, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S211 - S211
  • [9] Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis
    Swain, Sandra
    Cortes, Javier
    Xu, Binghe
    Lambertini, Chiara
    Essioux, Laurent
    Knott, Adam
    Restuccia, Eleonora
    Madjar, Katrin
    De Haas, Sanne Lysbet
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [10] Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population
    Saikia K.K.
    Panigrahi M.K.
    Mehta A.
    Kumar D.
    [J]. Indian Journal of Surgical Oncology, 2018, 9 (3) : 381 - 386
12345